RAD54L is altered in 0.5% of prostate carcinoma patients with RAD54L Mutation present in 0.34% of all prostate carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 15 clinical trials for prostate carcinoma, of which 12 are open and 3 are closed. Of the trials that contain RAD54L Mutation and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

Olaparib has evidence of efficacy in patients with RAD54L Mutation in prostate carcinoma [5].

RAD54L is altered in 0.81% of malignant solid tumor patients with RAD54L Mutation present in 0.63% of all malignant solid tumor patients [4].

RAD54L Mutation is an inclusion criterion in 30 clinical trials for malignant solid tumor, of which 24 are open and 6 are closed. Of the trials that contain RAD54L Mutation and malignant solid tumor as inclusion criteria, 13 are phase 1 (10 open), 7 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [5].

RAD54L is altered in 0.61% of breast carcinoma patients with RAD54L Mutation present in 0.36% of all breast carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 19 clinical trials for breast carcinoma, of which 15 are open and 4 are closed. Of the trials that contain RAD54L Mutation and breast carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), and 2 are phase 3 (2 open) [5].

RAD54L is altered in 0.51% of prostate adenocarcinoma patients with RAD54L Mutation present in 0.34% of all prostate adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 16 clinical trials for prostate adenocarcinoma, of which 15 are open and 1 is closed. Of the trials that contain RAD54L Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 13 are phase 2 (12 open), and 2 are phase 3 (2 open) [5].

RAD54L is altered in 0.46% of ovarian carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain RAD54L Mutation and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 6 are phase 2 (5 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD54L Mutation and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

RAD54L is altered in 3.03% of fallopian tube carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain RAD54L Mutation and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

RAD54L is altered in 0.57% of adenocarcinoma of the gastroesophageal junction patients with RAD54L Mutation present in 0.57% of all adenocarcinoma of the gastroesophageal junction patients [4].

RAD54L Mutation is an inclusion criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain RAD54L Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [5].

RAD54L is altered in 0.7% of non-small cell lung carcinoma patients with RAD54L Mutation present in 0.47% of all non-small cell lung carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD54L Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

RAD54L is altered in 0.61% of gastric carcinoma patients with RAD54L Mutation present in 0.41% of all gastric carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD54L Mutation and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.43% of pancreatic adenocarcinoma patients with RAD54L Mutation present in 0.38% of all pancreatic adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD54L Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

RAD54L is altered in 1.63% of small cell lung carcinoma patients with RAD54L Mutation present in 0.33% of all small cell lung carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD54L Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [5].

RAD54L is altered in 3.17% of endometrial carcinoma patients with RAD54L Mutation present in 2.87% of all endometrial carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD54L Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

RAD54L is altered in 1.71% of colorectal carcinoma patients with RAD54L Mutation present in 1.51% of all colorectal carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L Mutation and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

RAD54L is altered in 1.48% of urothelial carcinoma patients with RAD54L Mutation present in 1.29% of all urothelial carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

RAD54L is altered in 1.27% of cervical carcinoma patients with RAD54L Mutation present in 1.27% of all cervical carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

RAD54L is altered in 0.61% of gastric adenocarcinoma patients with RAD54L Mutation present in 0.41% of all gastric adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD54L Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

RAD54L is altered in 0.42% of pancreatic carcinoma patients with RAD54L Mutation present in 0.37% of all pancreatic carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD54L Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

RAD54L is altered in 0.22% of soft tissue sarcoma patients with RAD54L Mutation present in 0.22% of all soft tissue sarcoma patients [4].

RAD54L Mutation is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

RAD54L is altered in 0.49% of high grade ovarian serous adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

RAD54L is altered in 1.5% of bladder urothelial carcinoma patients with RAD54L Mutation present in 1.27% of all bladder urothelial carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L Mutation and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

RAD54L is altered in 1.09% of squamous cell lung carcinoma patients with RAD54L Mutation present in 0.91% of all squamous cell lung carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD54L Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

RAD54L is altered in 0.42% of head and neck squamous cell carcinoma patients with RAD54L Mutation present in 0.42% of all head and neck squamous cell carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD54L Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

RAD54L is altered in 0.35% of head and neck carcinoma patients with RAD54L Mutation present in 0.35% of all head and neck carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.3% of esophageal adenocarcinoma patients with RAD54L Mutation present in 0.3% of all esophageal adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L Mutation and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.25% of esophageal carcinoma patients with RAD54L Mutation present in 0.25% of all esophageal carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

RAD54L is altered in 0.23% of clear cell renal cell carcinoma patients with RAD54L Mutation present in 0.23% of all clear cell renal cell carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L Mutation and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

RAD54L is altered in 0.22% of gastrointestinal stromal tumor patients with RAD54L Mutation present in 0.22% of all gastrointestinal stromal tumor patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD54L Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.36% of non-hodgkin lymphoma patients with RAD54L Mutation present in 0.18% of all non-hodgkin lymphoma patients [4].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RAD54L Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

RAD54L Mutation is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L Mutation and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

RAD54L is altered in 22.22% of penile carcinoma patients with RAD54L Mutation present in 22.22% of all penile carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RAD54L is altered in 4.35% of pancreatic ductal adenocarcinoma patients with RAD54L Mutation present in 4.35% of all pancreatic ductal adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RAD54L is altered in 1.73% of colorectal adenocarcinoma patients with RAD54L Mutation present in 1.53% of all colorectal adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L is altered in 1.7% of malignant intestinal neoplasm patients with RAD54L Mutation present in 1.51% of all malignant intestinal neoplasm patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L is altered in 1.5% of malignant small intestinal neoplasm patients with RAD54L Mutation present in 1.5% of all malignant small intestinal neoplasm patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L is altered in 1.31% of melanoma patients with RAD54L Mutation present in 1.17% of all melanoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 2.22% of multiple myeloma patients with RAD54L Mutation present in 1.11% of all multiple myeloma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.67% of glioma patients with RAD54L Mutation present in 0.61% of all glioma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L is altered in 0.63% of malignant central nervous system neoplasm patients with RAD54L Mutation present in 0.57% of all malignant central nervous system neoplasm patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L is altered in 0.61% of malignant gastric neoplasm patients with RAD54L Mutation present in 0.41% of all malignant gastric neoplasm patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L is altered in 0.74% of neuroblastoma patients with RAD54L Mutation present in 0.37% of all neuroblastoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L is altered in 0.44% of malignant esophagogastric neoplasm patients with RAD54L Mutation present in 0.35% of all malignant esophagogastric neoplasm patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L is altered in 0.33% of leiomyosarcoma patients with RAD54L Mutation present in 0.33% of all leiomyosarcoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.48% of bile duct adenocarcinoma patients with RAD54L Mutation present in 0.32% of all bile duct adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L is altered in 0.48% of cholangiocarcinoma patients with RAD54L Mutation present in 0.32% of all cholangiocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.53% of diffuse large B-cell lymphoma patients with RAD54L Mutation present in 0.27% of all diffuse large B-cell lymphoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L is altered in 0.26% of renal cell carcinoma patients with RAD54L Mutation present in 0.26% of all renal cell carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.38% of biliary tract carcinoma patients with RAD54L Mutation present in 0.25% of all biliary tract carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.45% of B-cell non-hodgkin lymphoma patients with RAD54L Mutation present in 0.23% of all B-cell non-hodgkin lymphoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.49% of malignant ovarian epithelial tumor patients with RAD54L Mutation present in 0.08% of all malignant ovarian epithelial tumor patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L is altered in 1.01% of ampulla of vater carcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L is altered in 3.03% of high grade fallopian tube serous adenocarcinoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

RAD54L is altered in 0.63% of mantle cell lymphoma patients [4].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RAD54L Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].